Mesenchymal Stromal Cells Do Not Increase the Risk of Viral Reactivation Nor the Severity of Viral Events in Recipients of Allogeneic Stem Cell Transplantation
Table 2
Viral reactivations details.
UPN
Virus
Sample
Days from MSC infusion
Treatment
Outcome
1
EBV
Blood
100
Rituximab
Alive, no GvHD
4
CMV EBV
Blood Blood
13 40
Ganciclovir Rituximab
Alive, no GvHD
7
ADV
Blood + stool
7
Cidofovir
Alive, no GvHD
9
CMV
Blood
1
Ganciclovir
Died on day +456 from SCT from sepsis
10
CMV
Blood
2
Ganciclovir then Foscavir
Alive, no GvHD
11
ADV
Blood + stool
3
Cidofovir
Died on day +90 from SCT from GvHD
13
EBV
Blood
44
Rituximab
Alive, no GvHD
14
EBV CMV
Blood Blood + gut biopsy
1 7
Rituximab Ganciclovir+ Foscavir
Died on day +129 from SCT from sepsis
15
CMV EBV
Blood Blood
1 1
Ganciclovir None
Died on day +168 from SCT from septic shock
16
EBV CMV ADV
Blood Blood + gut biopsy Blood + gut biopsy
1 1 40
None Ganciclovir + Foscavir Cidofovir
Died on day +225 from SCT from GvHD
17
CMV
Blood
31
Ganciclovir
Died on day +136 from SCT from disease recurrence
EBV: Epstein Barr Virus, CMV: Cytomegalovirus, ADV: Adenovirus, GvHD: Graft versus Host Disease, and SCT: stem cellstransplantation.